BBIO
BridgeBio Pharma, Inc.
BBIO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BBIO PE Valuation
BBIO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
BBIO has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.04 | +$1.17 |
| Q2 2026 | -$3.57 | +$0.55 |
| Q1 2026 | -$3.74 | -$0.18 |
| Q4 2025 | -$3.78 | -$0.90 |
| Q3 2025 | -$4.21 | -$1.79 |
| Q2 2025 | -$4.12 | -$1.48 |
| Q1 2025 | -$3.56 | -$0.33 |
| Q4 2024 | -$2.88 | +$1.07 |
BBIO is still losing money, but less than at its worst: $3.04 per share over the past year, against $4.21 at its worst in late 2025.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over BBIO on earnings, with more consistent year-over-year improvement.
BBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $353.2M | +193% |
| Q2 2026 | $243.7M | +120% |
| Q1 2026 | $194.5M | +67% |
| Q4 2025 | $154.2M | +2521% |
| Q3 2025 | $120.7M | +4318% |
| Q2 2025 | $110.6M | +5000% |
| Q1 2025 | $116.6M | -45% |
| Q4 2024 | $5.9M | +237% |
BBIO's revenue has grown year over year for six quarters in a row: $353M last quarter, up 193% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.3% | +117 points |
| Q2 2026 | -44% | +78 points |
| Q1 2026 | -54% | +35 points |
| Q4 2025 | -91% | +3752 points |
| Q3 2025 | -120% | +6898 points |
| Q2 2025 | -121% | +7975 points |
| Q1 2025 | -89% | -90 points |
| Q4 2024 | -3843% | +6324 points |
BBIO has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$44.5M | +$65.6M |
| Q2 2026 | -$71.5M | +$9.7M |
| Q1 2026 | -$197.3M | +$1.9M |
| Q4 2025 | -$56.5M | +$138.9M |
| Q3 2025 | -$110M | +$70.7M |
| Q2 2025 | -$81.3M | -209% |
| Q1 2025 | -$199.2M | +$21M |
| Q4 2024 | -$195.4M | -$70.1M |
BBIO has burned cash in almost every quarter: −$370M over the past year, against −$586M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
BBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +244K shares |
| 1 year | +2.2% | +4.2M shares |
| 3 years | +20% | +32.7M shares |
| 5 years | +34% | +49.4M shares |
| Available history | +87% | +90.9M shares |
BBIO has 196M diluted shares, up 2.2% from a year ago, despite $253M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $42.5M |
| Q2 2026 | $127.5M |
| Q1 2026 | $82.5M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $48.3M |
| Q4 2021 | $1.5M |
BBIO spent $253M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BBIO Net Leverage
BBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 48.6 | Neutral |
BBIO's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BBIO PE vs Healthcare Sector
BBIO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $70.1 | 12% above |
| 20 week MA | $75.3 | 3.9% above |
| 50 week MA | $73.0 | 7.1% above |
| 100 week MA | $58.0 | 35% above |
| 200 week MA | $41.6 | 88% above |
BBIO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.8 | $69.5 | +89% |
| 2021 | $69.5 | $40.6 | -42% |
| 2022 | $40.6 | $7.88 | -81% |
| 2023 | $7.88 | $40.4 | +412% |
| 2024 | $40.4 | $28.0 | -31% |
| 2025 | $28.0 | $75.8 | +171% |
| 2026 YTD | $75.8 | $78.2 | +3.1% |
BBIO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.